Skip to main content
AUTL logo

AUTL · Autolus Therapeutics plc · Metrics

Track AUTL — free
$1.14 -0.03 (-2.56%) At close · Nov 16 Play latest call Q1 2026 earnings call transcript
Market Cap
$303.43M
Shares
266.16M
Volume · Nov 16 2.35M Avg daily vol (3M) 2.13M

AUTL metrics

76 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.14
Market cap
$303.43M

Price action

23 metrics
Price change (1W)
-13.6%
Price change (30D)
-28.3%
Price change (3M)
-50.0%
Price change (6M)
-36.7%
Price change (YTD)
-42.7%
Price change (1Y)
-16.8%
Trailing year
Price change (5Y)
-83.7%
52-week high
$2.54
52-week low
$1.14
Change from 52-week high
-55.1%
Change from 52-week low
+0.0%
Annualized volatility
73.1%
Annualized volatility (3M)
56.4%
Implied volatility (30D)
146.6%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.7
RSI (14D)
24.1
Price vs SMA 50
-32.0%
Price vs SMA 200
-31.2%
Avg volume (3M)
2.13M
Relative volume
1.1
Average dollar volume
$3.85M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
266.16M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.2×
reciprocal yield 45.3%
P / book
11.1
reciprocal yield 9.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-84.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-10

Profitability

9 metrics
Gross margin
35.8%
Operating margin
-159.6%
Trailing 12 months
Net margin
-186.4%
Gross profit (TTM)
$49.14M
Operating profit (TTM)
−$219.35M
Net income (TTM)
−$256.13M
Trailing 12 months
Diluted EPS (TTM)
$-0.97
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.52
Gross profit per diluted share (TTM)
$0.18
Operating profit per diluted share (TTM)
$-0.82
EBITDA per diluted share (TTM)
$-0.79
Net income per diluted share (TTM)
$-0.96
Operating cash flow per diluted share (TTM)
$-0.66
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.43
Stock compensation per diluted share (TTM)
—
Book value per share
$1.73

Growth

11 metrics
Revenue growth YoY
+94.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$137.43M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-934.9%
Return on assets
-49.0%
Debt / equity
—
Current ratio
3.7
EBITDA (TTM)
−$210.47M
Free cash flow (TTM)
—
Quick ratio
3.4
Interest coverage
-4.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$245.41M
Total assets
$523.06M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$176.24M
Capital expenditures (TTM)
$3.96M
R&D (TTM)
$115.64M
SG&A (TTM)
$152.85M
Stock compensation (TTM)
—
R&D / revenue
84.1%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
67
13F filer change QoQ
-16
Institutional ownership
19.2%
Conviction holders (share of 13F filers)
1.5%
Crowding (high-turnover and private-fund holders)
4.9%
Private-fund adviser ownership
4.6%
Active holders' share change QoQ
+16.8%
Holder tenure
15.5
Price vs estimated holder cost
-17.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.6%

Short interest

3 metrics
Short interest
3.2%
Latest settlement · 4.7 days to cover
Days to cover
4.7d
Short-squeeze score
44 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$15,682
Insider-sentiment score
52 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1730463 CUSIP 05280R100 13F (30d) 86 filings 71 filers Visit website Investor relations